Skip to main content
Premium Trial:

Request an Annual Quote

NCI Creates $104M Proteomics Cancer Plan; Taps Five Labs to Evaluate Tools, Methods

This update provides a link to the NCI page that lists the labs participating with the five principal centers.
NEW YORK (GenomeWeb News) – The National Cancer Institute today unveiled a $104 million Clinical Proteomic Technologies Initiative for Cancer.
NCI awarded a total of $35.5 million in grants over five years to establish a network of five teams for Clinical Proteomic Technology Assessment for Cancer, the agency said. The teams comprise: the Broad Institute of MIT and Harvard; University of California San Francisco/Lawrence Berkeley National Laboratory; Vanderbilt University School of Medicine; Purdue University; and Memorial Sloan-Kettering Cancer Center.
Each team will assess measurement technologies for proteins and peptides relevant to clinical cancer research and practice. Specifically, they will assess mass spectrometry and affinity capture platforms and evaluate the performance of various proteomic technology platforms. A list of the teams that comprise each of the five labs can be found here.
The NCI said standards will allow researchers conducting cancer-related protein research at different labs to use proteomic technologies and methodologies to directly compare and analyze their work.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.